e8vk
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Filed Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report
(Date of earliest event reported): March 20, 2009
Repros Therapeutics Inc.
(Exact name of registrant as specified in its charter)
| |
|
|
|
|
| Delaware
|
|
001-15281
|
|
76-0233274 |
| (State or other jurisdiction of
|
|
(Commission File Number)
|
|
(I.R.S. Employer Identification No.) |
| incorporation or organization) |
|
|
|
|
2408 Timberloch Place, Suite B-7
The Woodlands, Texas 77380
(Address of principal
executive offices
and zip code)
(281) 719-3400
(Registrant’s telephone
number, including area
code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see General Instruction
A.2 below):
| o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
| o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
| o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b)) |
| |
| o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c)) |
Item 7.01. Regulation FD Disclosure
On March 20, 2009, Repros Therapeutics Inc. (the “Company”) announced that it will hold its
annual meeting of shareholders on May 20, 2009, at 8:00 a.m. (Pacific Time) at the Inn at Rancho
Santa Fe, Rancho Santa Fe, CA. Shareholders of record as of March 23, 2009 will be entitled to
attend and vote at the meeting.
Item 8.01. Other Information
A copy of the Company’s press release is attached hereto as Exhibit 99.1. The press release
is incorporated by reference herein and the foregoing description of the press release is qualified
in its entirety by reference to the attached exhibit.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits
| |
|
|
| Exhibit |
|
|
| Number |
|
Description |
99.1
|
|
Press Release dated March 20, 2009 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
|
|
|
|
|
|
| |
|
Repros Therapeutics Inc. |
|
|
|
|
|
|
|
|
|
Date: March 20, 2009 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Louis Ploth, Jr. |
|
|
|
|
|
|
|
|
|
|
|
|
|
Louis Ploth, Jr.
Vice President, Business Development
and Chief Financial Officer |
|
|
EXHIBIT INDEX
| |
|
|
| Exhibit |
|
|
| Number |
|
Description |
99.1
|
|
Press Release dated March 20, 2009 |